|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2020
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/12245
Title: | Contemporary treatment of metastatic ovarian tumors |
Authors: | Șpac, Luminița |
Keywords: | metastatic cancer;treatment;oncogenicology |
Issue Date: | 2020 |
Publisher: | MedEspera |
Citation: | ȘPAC, Luminița. Contemporary treatment of metastatic ovarian tumors. In: MedEspera: the 8th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2020, p. 89-90. |
Abstract: | Introduction. Metastatic ovarian cancer is a serious worldwide public health problem, with
one of the highest potential for lethality among all tumors. It is an advanced malignancy, or
secondary tumor, with primary other organs, most commonly the gastrointestinal tract and
mammary gland, stomach, colon, appendix, uterus, lung. At present, the treatment of metastatic
ovarian tumors consists of several successive stages: surgical treatment, chemotherapy and
radiotherapeutic treatment. Patients with a metastatic limit only in the ovary have a favorable
prognosis, or usually. Adjuvant chemotherapy after metastasis resection offers survival
benefits in gastric and colorectal cancer. The ovary is a frequent site of involvement for
metastases. Ovarian involvement is observed at autopsy in approximately 10% of breast cancer
cases. Metastasis is bilateral around 80% of patients. About 5-30% of ovarian cancers are
metastatic malignancies.
Aim of the study. To study the techniques and principles of treatment for metastatic ovarian
tumors
Materials and methods.. Lot of patients: 53 patients with metastatic ovarians tumors were
hospitalized and treated in IMSP IO from Moldova during 2012-2019
Results. Total enrolled: 53 patients, age with the highest incidence - 41-50 years - 18 patients
(33.9%) Histological distribution: signet ring cell - 26 patients( 49.1%), adenocarcinoma – 24
patients ( 45.2%), clear cell carcinoma - 3 patients (5.66%). After the primary outbreak - the
highest incidence for the stomach cancer - 25 patients (47.1%) and uterus cancer- 17 patients
(32.07%).For the colorectal cancer the incidence is 9.43%- 5 patients, uterin cervical cancer3.77%- 2 ,mammary gland cancer-5,66%- 3 patients and for cancer without clarification-1,88
%- 1 patient. Bilaterality is prevalent in our study with 62.2% (33 persons) Of them treated
surgically: 53 patients-100% ,treated only with adjuvant chemotherapy: 40 patints- 75,47 %,treated only with radiotherapy- 7 patients- 13.2 %, combined treatment- 6 patients- 11,3%.
Chemotherapy treatment consists of complex treatment regimens containing at least 2
chemotherapeutic preparations. The patients has be treated with fluorouracil, doxorubicin,
cisplatin, cyclophosphamide .We can mention that fluorouracil was used by 28 patients,
doxorubicin-24, cisplatin -30, cyclophosphamide-14.
Conclusions. Treatment for metastatic cancer aims to slow the growth or spread of the cancer.
The treatment depends on the type of cancer, where it started, the size and location of the
metastasis, and other factors. Even if metastatic cancer has stopped responding to treatment,
many therapies may help ease side effects and improve quality of life. |
URI: | https://medespera.asr.md/wp-content/uploads/ABSTRACT-BOOK.pdf http://repository.usmf.md/handle/20.500.12710/12245 |
Appears in Collections: | MedEspera 2020
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|